Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Trial details
- Registry ID
- NCT04365868
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as GR-MD-02; galactoarabino rhamnogalacturonate
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisNCT04365868 | GALT | Phase 2, Phase 3 | Terminated | 2025-03-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |